A population pharmacokinetic model of AT9283 in adults and children to predict the maximum tolerated dose in children with leukaemia

Duong Janna K.; Griffin Melanie J.; Hargrave Darren; Vormoor Josef; Edwards David; Boddy Alan V.

首页> 外文期刊>British Journal of Clinical Pharmacology >A population pharmacokinetic model of AT9283 in adults and children to predict the maximum tolerated dose in children with leukaemia

【24h】

A population pharmacokinetic model of AT9283 in adults and children to predict the maximum tolerated dose in children with leukaemia

机译：成人和儿童AT9283的人口药代动力学模型预测白血病儿童最大耐受剂量

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

AimsAT9283 is used to treat patients with solid tumours and patients with leukaemia. However, the maximum tolerated dose (MTD) for children with leukaemia remains unknown due to early termination of the Phase I trial. The aim of this study was to develop a population model of AT9283 to describe the pharmacokinetics in adults and children and to estimate the MTD in children with leukaemia.

机译：AIMSAT9283用于治疗患有实体肿瘤和白血病患者的患者。然而，由于I期试验期初终止，白血病儿童的最大耐受剂量（MTD）仍然未知。本研究的目的是开发AT9283的人口模型，以描述成人和儿童的药代动力学，并估计白血病儿童的MTD。

著录项

来源
《British Journal of Clinical Pharmacology》 |2017年第8期|共10页
作者
Duong Janna K.; Griffin Melanie J.; Hargrave Darren; Vormoor Josef; Edwards David; Boddy Alan V.;
展开▼
作者单位

Univ Sydney Fac Pharm Pharm &

Bank Bldg A15 Sydney NSW Australia;

Northern Inst Canc Res Newcastle Upon Tyne Tyne &

Wear England;

Great Ormond St Hosp Children NHS Fdn Trust London England;

Northern Inst Canc Res Newcastle Upon Tyne Tyne &

Wear England;

Canc Res UK London England;

Univ Sydney Fac Pharm Pharm &

Bank Bldg A15 Sydney NSW Australia;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类药理学;
关键词
aurora kinase inhibitor; maximum tolerated dose; paediatric; pharmacokinetics; phase I oncology trial;

机译：极光激酶抑制剂;最大耐受剂量;儿科;药代动力学;I期肿瘤学审判;

相似文献

外文文献
中文文献
专利

1. A population pharmacokinetic model of AT9283 in adults and children to predict the maximum tolerated dose in children with leukaemia [J] . Janna K. Duong, Melanie J. Griffin, Darren Hargrave, British journal of clinical pharmacology . 2017,第8期

机译：成人和儿童中AT9283的群体药代动力学模型可预测白血病儿童的最大耐受剂量
2. A population pharmacokinetic model of AT9283 in adults and children to predict the maximum tolerated dose in children with leukaemia [J] . Duong Janna K., Griffin Melanie J., Hargrave Darren, British Journal of Clinical Pharmacology . 2017,第8期

机译：成人和儿童AT9283的人口药代动力学模型预测白血病儿童最大耐受剂量
3. A population pharmacokinetic model of AT9283 in adults and children to predict the maximum tolerated dose in children with leukaemia [J] . Duong Janna K., Griffin Melanie J., Hargrave Darren, British Journal of Clinical Pharmacology . 2017,第8期

机译：成人和儿童AT9283的人口药代动力学模型预测白血病儿童最大耐受剂量
4. Indonesian anthropometry update through Drillis Contini revisited and Structural Equation Modeling incorporating children, adult and elderly populations [C] . M. Hartono IEEE International Conference on Industrial Engineering and Engineering Management . 2016

机译：通过Drillis＆Contini的印度尼西亚人体测量学更新，以及结合儿童，成人和老年人口的结构方程模型更新
5. Applications of Physiologically Based Pharmacokinetic Modelling to Prediction of the Likelihood of Metabolic Drug Interactions in Paediatric Population and Studying Disparities in Pharmacokinetics Between Children and Adults [D] . Salem, Farzaneh. 2014

机译：基于生理的药代动力学模型在小儿人群中代谢药物相互作用的可能性预测和研究儿童与成人之间药代动力学差异的应用
6. A population pharmacokinetic model of AT9283 in adults and children to predict the maximum tolerated dose in children with leukaemia [O] . Janna K. Duong, Melanie J. Griffin, Darren Hargrave, 2017

机译：成人和儿童中AT9283的群体药代动力学模型可预测白血病儿童的最大耐受剂量
7. 229: Twice-Daily Intravenous (IV) Busulfan (Bu) x 4 Days in Children Undergoing a Reduced-Intensity Conditioning (RIC) Regimen with Allogeneic Hematopoietic Stem Cell Transplantation (AlloHSCT) is Safe and Well-Tolerated but Results in Significantly Increased Bu Clearance (CL) and Decreased Area Under the Curve (AUC) and Half-Life (t1/2) When Compared to IV Bu Twice-Daily Dosing Pharmacokinetics (PK) in Adults [O] . Waxman I., Bhatia M., Milone M., 2008

机译：229：接受同种异体造血干细胞移植（AlloHSCT）的减低强度调节（RIC）方案的儿童，每天两次静脉（IV）白消安（Bu）x 4天是安全且耐受性良好的，但可显着提高Bu清除率（CL）和减少的曲线下面积（AUC）和半衰期（t1 / 2）与成人静脉内两次每日剂量药代动力学（PK）相比

A population pharmacokinetic model of AT9283 in adults and children to predict the maximum tolerated dose in children with leukaemia

摘要

著录项

相似文献

相关主题

期刊订阅